<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8197D033-4017-48BD-8AF5-7BCB6AE203AB"><gtr:id>8197D033-4017-48BD-8AF5-7BCB6AE203AB</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>John</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400197"><gtr:id>033CB89B-3191-4FF6-B58C-A51927364B20</gtr:id><gtr:title>Regulation of Stat5 activity in peripheral T cells: Dysregulation in Sezary Syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400197</gtr:grantReference><gtr:abstractText>Cytokines, are proteins that act as messengers to elicit important biological changes in many aspects of the normal function of the body. The cytokine that is the subject of this study is called interleukin-2 (IL-2), which directly affects T cells and has been shown to play a central role in the development and function of several components of the immune system. IL-2 exerts its effect by mobilizing specialized intracellular proteins in T cells, called signal transducers and activators of transcription (STAT), whose ultimate function is to reprogramme gene expression allowing the responding cell to make an appropriate biological response. STAT proteins critically control the life and death decisions of T cells and consequently are often deleteriously altered in human cancers such as leukamias and lymphomas. We recently described the aberrant function of one member of this family, namely Stat5, in malignant T cells from a common human skin-related cancer called Sezary Syndrome. We found T cells from patients showed a breakdown of the processes, which in healthy individuals maintains this protein in two different structural forms; one of which positively affects gene expression, while the other has a negative effect. The inhibitory form of the protein is predominantly expressed in cancer cells leading to deleterious consequences on IL-2-activated gene expression. In this proposal, we will elucidate the mechanisms that control the generation and activity of Stat5 proteins in normal human T cells. By studying how these processes differ in normal versus cancer cells, we hope to gain a better understanding of not only normal T cell function but also how it is dysregulated in cancer. These studies may also inform on possible therapeutic approaches for T cell malignancy.</gtr:abstractText><gtr:technicalSummary>Signal transducers and activators of transcription (STAT) proteins are vital mediators of signalling downstream of myriad cytokine and growth factor receptors, including the immunologically important interleukin-2 (IL2) family of cytokines. STAT proteins critically regulate cell growth, differentiation and proliferation and consequently are often constitutively activated in many varieties of human tumours. We recently showed that Sezary Syndrome (SzS), a relatively common T cell malignancy, is characterised by aberrant downregulation of Stat5. We showed that the basis for Stat5 dysfunction lies in its complex regulation, previously unknown in T cells: Stat5 exists both as a full length form, and as a carboxy -terminal truncated protein (Stat5t), generated by an unidentified proteolytic activity. Significantly, we showed that there is dysregulated expression of Stat5t in Sezary Syndrome leading to a loss of IL-2-induced Stat5-dependent gene expression. In this proposal, we will undertake studies aimed at understanding the molecular processes that regulate the functional activity of Stat5 in normal peripheral T cells, 
Specifically we will:
1. Characterise and biochemically purify the Stat5 protease.
2. Study the role of cytidine deamination in the regulation of Stat5 gene expression.
3. Examine the functional expression of Stat5 in CD4+ CD25+ regulatory T cells.

These studies will greatly enhance our understanding of Stat5 expression and function in normal T cell and also how these processes may be dysregulated in diseases.
My position in the Immunobiology department is lecturer.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-05-23</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>408761</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Cytokine signalling in healthy and CTCL patient Treg cells</gtr:description><gtr:id>75F7FE46-26E0-45CA-BC6A-7ECA6DE21FAF</gtr:id><gtr:impact>Two manuscripts published (18042719, 16741512). Both sets of research have been presented at international meetings over the period of 4 years.</gtr:impact><gtr:outcomeId>9D09746D543-1</gtr:outcomeId><gtr:partnerContribution>directional, intellectual and experimental contributions</gtr:partnerContribution><gtr:piContribution>Directional, intellectual, financial, and experimental contributions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Transplantation</gtr:department><gtr:description>CD4+Cd25+ Treg to Th17 conversion</gtr:description><gtr:id>3DF30065-1037-4BD6-A740-75A534652CE6</gtr:id><gtr:impact>One publication already (19912251),and two more to be submitted shortly. We have presented this work at international conferences over 2008-2010; BSI Glasgow (2008), FOCIS (2009) USA: ICS (2009) Lisbon, BSI -Liverpool 2010. KCL BRC-NIHR funding awarded jointly to collaborators in 2010.</gtr:impact><gtr:outcomeId>89408F1C387-1</gtr:outcomeId><gtr:partnerContribution>Mutually beneficial research, access to facilities</gtr:partnerContribution><gtr:piContribution>I have made intellectual, directional and experimental (and provision of reagents) contributions towards this collaboration.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Stat5 Dysregulation In Sezary Syndrome</gtr:description><gtr:id>9A5EF7BC-9F6A-47B7-B12F-376DE0315F98</gtr:id><gtr:impact>Four manuscripts published, one of which is reported here (16741512). The work has been presented by both parties at separate International meetings since 2004</gtr:impact><gtr:outcomeId>81EA5AB708E-1</gtr:outcomeId><gtr:partnerContribution>They have provided ethically approved, patient sample material used in this research.</gtr:partnerContribution><gtr:piContribution>Directional, Intellectual, Financial and experimental contributions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Stat5 function in health and disease</gtr:description><gtr:id>5F3F03D1-7178-4DCF-ABE2-CF0DCC766C28</gtr:id><gtr:impact>Publication in 2011 in Journal of Immunology; PMID: 21876034</gtr:impact><gtr:outcomeId>robXyVXbFyd-1</gtr:outcomeId><gtr:partnerContribution>We continue to collaborate on investigating the function of other genes, that were identified by this study, in T cells and their relevance in inflammation and allergy.</gtr:partnerContribution><gtr:piContribution>Directed and designed the research, performed experiments, interpreted results, wrote the manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Student work experience-London</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5E50B244-029A-4349-99F9-1CEE35E0FA4D</gtr:id><gtr:impact>One student at a time comes to work in my lab for a week and is taught about the research we perform and is provided wet lab experience. Students have to then report their week's experience in a verbal presentation to their class at school.

Have been invited by School to present a lecture to students in the future and assist in organizing science-related activities in the future</gtr:impact><gtr:outcomeId>32D7DDF0ADD</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>informing health professionals</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8068D147-C0B2-46A7-9079-0F54B19E8504</gtr:id><gtr:impact>Our paper on c-maf regulation by IL-2 was selected to be highlighted by MDLinx (www.MDLinx.com) on Sept. 29th 2011. MDLinx is the world's most up-to-date index of articles that matter in the daily lives of physicians and other healthcare professionals. Every day they send almost 1,000,000 free briefings across 35 specialty areas.

paper has already been cited by other researchers since it was published in October 2011.</gtr:impact><gtr:outcomeId>MMK1AR2M848</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Module organizer for course in MSc Immunology</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E35DA58F-FD8B-4B17-88B0-654F3B05CCE8</gtr:id><gtr:impact>Educating future workforce in the academic and clinical service delivery fields</gtr:impact><gtr:outcomeId>Xz7RDcKHn36</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Academic advisor on PhD Progress Committees</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>19ADC7CD-0EFD-4968-A3F2-645E86FFE53D</gtr:id><gtr:impact>students will successfully graduate through guidance received through these PG committees</gtr:impact><gtr:outcomeId>fEbga23QnXF</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External Examiner for PhD vivas</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>32964AF7-ADF8-4828-B3CC-7CE28EDD7F32</gtr:id><gtr:impact>New postgraduates will contribute to the economics through getting jobs matching their skills, usually in the healthcare industry</gtr:impact><gtr:outcomeId>BxZe5AChSDq</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>AS part of a Wellcome Trust funded study, now completed, a collection of Stat5-target genes were identified in CD4 and CD8 T cells, by chromatin-immunoprecipitation analysis. Many of these genes have associations with cancer and other diseases and therefore could provide novel insights into how the dsyregulation of Stat5 in diesases such as cancer, including Sezary Syndrome, which is relevant to this grant, contributes towards malignant pathogenesis. Specific genes selected from the 6 databases generated, have been functionally studied in this MRC grant. Given the importance of Stat5 function in autoimmunity and cancer for eg, some of these genes may in the future provide useful biomarkers or be used as candidates for therapeutic targeting. In 2009 we signed an MTA with Rigel Pharmaceuticals, Ca. USA to use their JAK3 inhibitor in the functional analysis of these genes. In light of the possible use of these for therapeutic targeting, I have been approached by a small bio-pharma company in India (Piramal Life Sciences) to interact with them to test their compounds in our studies. As the collaboration has not been finalized it will not be reported here at this time. We are initiating IP talks with Kings Business on the findings reported in a manuscript under revision at Journal of Immunology.</gtr:description><gtr:id>6D5E4B96-9E60-41FE-A737-F625C78C855F</gtr:id><gtr:impact>One manuscript currently (2010) under revision at Journal of Immunology. Presentation of work at international conferences; ICS/ISICR, USA 2007; BSI, UK, 2008, ICS/ISICR/SLB Joint meeting, Lisbon 2009: ICS/ISICR , Chicago USA 2010.</gtr:impact><gtr:outcomeId>DAA61BAF327</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>T cell Stat5-ChIP</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E1F35FBA-9672-47A0-80BD-3CCEAA238DF8</gtr:id><gtr:title>Identification and analysis of Il-2 induced Stat5 Target genes in Human CD4 and CD8 T cells</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/94d5a3f2ccbf2a846b2bc29ed38718fd"><gtr:id>94d5a3f2ccbf2a846b2bc29ed38718fd</gtr:id><gtr:otherNames>Rani Aradhana</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>5aa791285376b2.31064061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A2993E6-5771-4F62-97B7-FDD1B456DCDD</gtr:id><gtr:title>CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/398da9bece88cd3060aedfa4b39803bd"><gtr:id>398da9bece88cd3060aedfa4b39803bd</gtr:id><gtr:otherNames>Tiemessen MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>556CAA1F973</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B67E8D3-CAB0-463B-8F82-9B6FC44E3B73</gtr:id><gtr:title>Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>DB4998489FF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1303E82-8E6D-4E2B-8A0D-43B83C54AA80</gtr:id><gtr:title>Purification and identification of the STAT5 protease in myeloid cells.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d2bbeee935e84764e750544250e4fff"><gtr:id>8d2bbeee935e84764e750544250e4fff</gtr:id><gtr:otherNames>Schuster B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>5BF775C4345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF9A0199-7379-4132-B17B-741C6B154292</gtr:id><gtr:title>Thymic versus induced regulatory T cells - who regulates the regulators?</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a2e56aa70edca4379a30f43d2072b4f8"><gtr:id>a2e56aa70edca4379a30f43d2072b4f8</gtr:id><gtr:otherNames>Povoleri GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>iCJkpDKFtAJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>634C0CE7-EF28-4204-92FD-63AC5F32D7F4</gtr:id><gtr:title>CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>M97eKEVLQUx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FC26B8E-6671-4BF9-BA7F-BA0B9D84F941</gtr:id><gtr:title>Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/398da9bece88cd3060aedfa4b39803bd"><gtr:id>398da9bece88cd3060aedfa4b39803bd</gtr:id><gtr:otherNames>Tiemessen MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>A37EF32F2E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4C69C87-A4E4-4EC7-A58B-DA3C3B215671</gtr:id><gtr:title>T-cell receptor early signalling complex activation in response to interferon-alpha receptor stimulation.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b62b2a287607005b2e57b469233f1b"><gtr:id>a8b62b2a287607005b2e57b469233f1b</gtr:id><gtr:otherNames>Stevens CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>45F40D8B814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71CF869D-26B0-429A-9565-A1720C38B875</gtr:id><gtr:title>Relative resistance of human CD4(+) memory T cells to suppression by CD4(+) CD25(+) regulatory T cells.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>sr9Tq1frV3s</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90ECD2B4-80FF-4A9A-94EC-27FA5446C83A</gtr:id><gtr:title>IL-2 regulates expression of C-MAF in human CD4 T cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4bd41f5e795706d066b9db464defb69"><gtr:id>d4bd41f5e795706d066b9db464defb69</gtr:id><gtr:otherNames>Rani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>bTe5w28u1S9</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400197</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>